INTRODUCTION
Colorectal cancer, co mmonly known as bowel cancer, is a cancer caused by uncontrolled cell growth (neoplasia), in the colon, rectum, or vermiform appendix. Colorectal cancer is clin ically distinct fro m anal cancer, which affects the anus.Invasive cancers that are confined within the wall of the colon (TNM stages I and II) are often curable with surgery, For example, in England and Wales over 90% o f patients diagnosed at this stage will survive the disease beyond 5 years. However, if left untreated, the cancer can spread to regional ly mph nodes (stage III) around 48% of patients diagnosed at this stage survive the disease beyond five years. Cancer that has spread widely around the body (s tage IV) is usually not curable appro ximately 7% of patients diagnosed at this stage survive beyond five years. 1 Colorectal cancer is the third most commonly diagnosed cancer in the world, but it is mo re common in developed countries . More than half of the people who die of colorectal cancer live in a developed region of the world. GLOBOCA N estimated that, in 2008, 1.23 million new cases of colorectal cancer were clin ically diagnosed, and that this type of cancer killed mo re than 600,000 people. 
SYMPTOMS
Local symptoms are more likely if the tu mor is located closer to the anus. There may be a change in bowel habit (such as unusual and unexplained constipation or diarrhea), and a feeling of incomp lete defecation (rectal tenesmus). Lower gastrointestinal bleeding, including the passage of bright red blood in the stool, may indicate colorectal cancer, as may the increased presence of mucus. Melena, black stool with a tarry appearance, normally occurs in upper gastrointestinal bleeding (such as from a duodenal ulcer), but is sometimes encountered in colorectal cancer when the disease is located in the beginning of the large bowel.
A tumor that is large enough to fill the entire lu men of the bowel may cause bowel obstruction. This situation is characterized by constipation, abdominal pain, and abdominal distension and vomiting. This occasionally leads to the obstructed and distended bowel perforat ing and causing peritonitis. A large left co lonic tu mor may co mpress the left ureter and cause hydronephrosis. 4 Certain local effects of colorectal cancer occur when the disease has become more advanced. A large tu mor is mo re likely to be noticed on feeling the abdomen, and it may be noticed by a doctor on physical examination. The disease may invade other organs, and may cause blood or air in the urine (invasion of the bladder) or vaginal d ischarge (invasion of the female reproductive tract.
o Family h istory of colon cancer, especially in a close relative before the age of 55 or mu ltiple relatives. Lithocholic acid: Lithocholic acid is a bile acid that acts as a detergent to solubilize fats for absorption. It is made fro m chenodeoxycholic acid by bacterial action in the colon. It has been implicated in hu man and experimental animal carcinogenesis.
Viruses: Exposure to some viruses (such as particular strains of human papillo ma virus) may be associated with colorectal cancer.
Primary sclerosing cholangitis offers a risk independent to ulcerative colitis. Exogenous hormones. The differences in the time trends in colorectal cancer in males and females could be explained by cohort effects in exposure to some genderspecific risk factor; one possibility that has been suggested is exposure to estrogens. In contrast, there is evidence that exogenous estrogens such as hormone replacement therapy (HRT), Tamo xifen or oral contraceptives might be associated with colorectal tumors.
Alcohol: Drinking, especially heavily, may be a risk factor.
Vitamin B 6 intake lo wers the risk o f colorectal cancer.
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Globally, cancer o f the colon and rectum is the third leading cause of cancer in males and the fourth leading cause of cancer in females. The frequency of colorectal cancer varies around the world. It is common in the Western world and is rare in Asia and Africa. In countries where the people have adopted western diets, the incidence of colorectal cancer is increasing.
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RECTAL CANCER:
Rectal cancer occurs when cancerous cells develop in the tissue of the rectum. The rectu m is the last part of the large intestine and leads to the anus, which is the opening to the outside of the body. Body waste is stored in the rectum until it is eliminated fro m the body through the anus.
Although rectal cancer is a life -threatening disease, it is a highly curable fo rm of cancer if found early. Therefore, regular check-ups and screenings are very important.
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SIGN AND S YMPTOMS : 14
Co mmon signs and symptoms of rectal cancer include: 
WHAT IS CANCER OF THE COLON AND RECTUM?
The colon is the part of the digestive system where the waste material is stored. The rectum is the end of the colon adjacent to the anus. Together, they form a long, muscular tube called the large intestine (also known as the large bowel). 
Diet and col on cancer
Diets high in fat are believed to predispose humans to colorectal cancer. In countries with high colorectal cancer rates, the fat intake by the population is much higher than in countries with lo w cancer rates. It is believed that the breakdown products of fat metabolis m lead to the formation of cancer-causing chemicals (carcinogens). Diets high in vegetables and high-fiber foods such as whole-grain breads and cereals may rid the bowel of these carcinogens and help reduce the risk of cancer.
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Col on pol yps and col on cancer 
Ulcerati ve colitis and colon cancer
Chronic ulcerative colitis causes inflammation of the inner lin ing of the colon. For further information, please read the Ulcerative Colitis article. Colon cancer is a recognized complication of chronic ulcerative colitis. 18 The risk for cancer begins to rise after eight to 10 years of colit is. The risk of developing colon cancer in a patient with ulcerative colitis also is related to the location and the extent of his or her disease. 19 Current estimates of the cu mulative incidence of colon cancer associated with ulcerative colitis are 2.5% at 10 years, 7.6% at 30 years, and 10.8% at 50 years. Patients at higher risk of cancer are those with a family history of colon cancer, a long duration of colit is, extensive colon involvement, and those with primary sclerosing cholangitis (PSC).
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Genetics and colon cancer 21
A person' s genetic background is an important factor in colon cancer risk. A mong first-degree relat ives of colon cancer patients, the lifetime risk of developing colon cancer is 18% (a threefold increase over the general population in the United States).
Even though family history of colon cancer is an important risk factor, majority (80%) of co lon cancers occur sporadically in patients with no family history of colon cancer. Approximately 20% of cancers are associated with a family history of colon cancer. And 5 % of colon cancers are due to hereditary colon cancer syndromes. Hereditary colon cancer syndromes are disorders where affected family members have inherited cancer-causing genetic defects from one or both of the parents.
Chro mosomes contain genetic informat ion, and chromosome damages cause genetic defects that lead to the formation of colon polyps and later colon cancer. In sporadic polyps and cancers (polyps and cancers that develop in the absence of family history), the chromosome damages are acquired (develop in a cell during adult life). 22 The damaged chromosomes can only be found in the polyps and the cancers that develop from that cell. But in hereditary colon cancer syndromes, the chromosome defects are inherited at birth and are present in every cell in the body. Patients who have inherited the hereditary colon cancer syndrome genes are at risk of developing large nu mber of colon polyps, usually at young ages, and are at very high risk of developing colon cancer early in life, and also are at risk of developing cancers in other organs. 23 HNPCC (hereditary nonpolyposis colon cancer) is a hereditary colon cancer syndrome where affected family members can develop colon polyps and cancers, usually in the right colon, in their 30s to 40s. Certain HNPCC patients are also at ris k of developing uterine cancer, stomach cancer, ovarian cancer, and cancers of the ureters (the tubes that connect the kidneys to the bladder), and the biliary tract (the ducts that drain bile fro m the liver to the intestines).
MYH polyposis syndrome is a recently discovered hereditary colon cancer syndrome. Affected members typically develop 10-100 polyps occurring at around 40 years of age, and are at high risk o f developing colon cancer.
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SCREENING FOR COLORECTAL CANCER:
Colorectal cancer (CRC) is preventable by removing pre-cancerous lesions or adenomatous polyps long before invasive cancer develops. For the general population, screening is advised starting at age 50. 
4.
Sig mo idoscopy is an invasive procedure using a 60 cm flexib le lighted tube inserted into the rectum and can visualize the lower part of the colon. A video camera is at the end of the scope and images are visualized on a display monitor. Polyps can be biopsied and removed through the scope. This procedure can be done without sedation. 29 The greatest limitat ion of this procedure is that it can identify premalignant and malignant lesions in only half of the colon. Abnormal findings will result in the patient needing to undergo a colonoscopy.
5.
Colonoscopy is an invasive procedure through which the entire length of the colon is visualized through a colonoscope. Similar to the sigmoidoscope, it has a video camera on the end which allo ws the endoscopist to closely view the colon on a display screen. Biopsy and removal of suspicious findings can be done during the procedure. Patients typically receive anesthesia for this procedure.
6. Double-Contrast Bariu m Enema (DCBE) or lower gastrointestinal series. This procedure done in the radiology department entails the insertion of a small flexib le tube into the rectum through which bariu m is in jected. Air is injected following the barium to assist in expansion. DCBE is insensitive to detecting small or flat adenomas and is only recommended when a total colonoscopy cannot be completed.
7.
Co mputerized To mography (CT) Colonoscopy or virtual colonoscopy uses 3-dimensional imag ing. Du ring this test the patient will lie on a table and a small flexible tube is inserted into the rectum through which air is pumped in to expand the colon for better visualization. Positive findings on this test will require follow-up with a colonoscopy. 3 Individuals ≥ 50-years-old with no personal history of adenoma, CRC or inflammatory bowel disease or a family history of CRC are considered at average risk for developing colorectal cancer. Their lifetime risk for developing CRC is about 1 in 19 (5.2%).
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STAGE GROUPING TNM S TAGING S YS TEM 11
The TNM Classification of Malignant Tumors (TNM) is a cancer staging system that describes the extent of cancer in a patient's body.
T describes the size of the tumors and whether it has invaded nearby tissue, N describes regional ly mph node that are involved, M describes distant metastasis (spread of cancer fro m one body part to another).
The TNM staging system for all solid tumors was devised by Pierre Denoix between 1943 and 1952, using the size and extension of the primary tu mor, its ly mphatic involvement, and the presence of metastases to classify the progression of cancer.
TNM is developed and maintained by the International Union against Cancer (UICC) to achieve consensus on one globally recognized standard for classifying the extent of spread of cancer. The TNM classification is also used by the American Joint Co mmittee on Cancer (AJCC) and the International Federation of Gynecology and Obstetrics (FIGO). 
Stage 0
Tis, N0, M0: The cancer is in the earliest stage. It has not grown beyond the inner layer (mucosa) of the colon or rectu m. This stage is also known as carcino ma in situ or intramucosal carcino ma.
Stage I
T1-T2, N0, and M0: The cancer has grown through the muscularis mucosa into the submucosa (T1) or it may also have grown into the muscularis propria (T2). It has not spread to nearby lymph nodes or distant sites.
Stage IIA
T3, N0, M 0: The cancer has grown into the outermost layers of the colon or rectum but has not gone through them (T3). It h as not reached nearby organs. It has not yet spread to the nearby ly mph nodes or distant sites.
Stage IIB
T4a, N0, and M 0: The cancer has grown through the wall of the colon or rectum but has not grown into other nearby tissues or organs (T4a). It has not yet spread to the nearby lymph nodes or distant sites.
Stage IIC
T4b, N0, M 0: The cancer has grown through the wall of the colon or rectum and is attached to or has grown into other nearby tissues or organs (T4b). It has not yet Spread to the nearby lymph nodes or distant sites.
Stage IIIA
One of the following applies.
T1-T2, N1, and M0: The cancer has grown through the mucosa into the submucosa (T1) and it may also have grown into the muscularis propria (T2). It has spread to 1 to 3 nearby ly mph nodes (N1a/N1b) or into areas of fat near the ly mph nodes but not the nodes themselves (N1c). It has not spread to distant sites.
Stage IIIB
T3-T4a, N1, and M0: The cancer has grown into the outermost layers of the colon or rectum (T3) or through the visceral peritoneum (T4a) but has not reached nearby organs. It has spread to 1 to 3 nearby ly mph nodes (N1a/ N1b) or into areas of fat near the ly mph nodes but not the nodes themselves (N1c). It has not spread to distant sites.
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T2-T3, N2a, and M0: The cancer has grown into the muscularis propria (T2) or into the outermost layers of the colon or rectum (T3). It has spread to 4 to 6 nearby lymph nodes (N2a). It has not spread to distant sites.
T1-T2, N2b, and M0: The cancer has grown through the mucosa into the submucosa (T1) or it may also have grown into the muscularis propria (T2). It has spread to 7 or more nearby lymph nodes (N2b). It has not spread to distant sites.
Stage IIIC
T4a, N2a, and M0: The cancer has grown through the wall of the colon or rectum (including the visceral peritoneum) but has not reached nearby organs (T4a). It has spread to 4 to 6 nearby ly mph nodes (N2a). It has not spread to distant sites.
T3-T4a, N2b, and M0: The cancer has grown into the outermost layers of the colon or rectum (T3) or through the visceral peritoneum (T4a) but has not reached nearby organs. It has spread to 7 or more nearby ly mph nodes (N2b). It has not spread to distant sites.
T4b, N1-N2, and M0: The cancer has grown through the wall of the colon or rectum and is attached to or has grown into other nearby tissues or organs (T4b). It has spread to at least one nearby lymph node or into areas of fat near the lymph nodes (N1 or N2). It has not spread to distant sites. may not have spread to nearby lymph nodes. It has spread to more than 1 distant organ (such as the liver or lung) or set of ly mph nodes, or it has spread to distant parts of the peritoneum (the lin ing of the abdominal cavity) (M 1b).
Preventi on:
Most colorectal cancers should be preventable, through increased surveillance, improved lifestyle, and, probably, the use of dietary chemo preventative agents.
TERATMENT
Treat ment for rectal cancer may include surgery, chemotherapy or radiat ion therapy, or a co mbination of these approaches. Surgery is the main t reat ment for all stages of rectal cancer, although radiation, chemotherapy, or both are often recommended in co mbination. So me patients who undergo surgery for rectal cancer require a permanent colostomy a surgically created opening in the abdominal wall through which waste is excreted. 
Related Treatment Information:
Angiogenesis Inhibitors Therapy A fact sheet that describes the process of eliminating the blood supply to tumors. Lists the cancers in which this approach is being tested.
Biological Therapies for Cancer
A fact sheet that provides an overview of how the immune system functions and describes the actions of biological therapies.
Radiation Therapy for Cancer
A fact sheet that defines the different types of radiation therapy and discusses scientific advances that imp rove the effectiveness of this treatment.
Targeted Cancer Therapies
This NCI fact sheet describes targeted cancer therapies, which are drugs that block the growth and spread of cancer by interfering with specific molecules involved in carcinogenesis (the process by which normal cells are transformed into cancer cells) and tu mor growth.
Chemotherapy
Chemotherapy is used to reduce the likelihood of metastasis developing, shrink tumor size, or slow tu mor gro wth.
Chemotherapy is often applied after surgery (adjuvant), before surgery (neoadjuvant), or as the primary therapy (palliative). The treatments listed here have been shown in clinical trials to improve survival and/or reduce mortality rate, and have been approved for use by the US Food and Drug Administration. In colon cancer, chemotherapy after surgery is usually only given if the cancer has spread to the lymph nodes(Stage III).
Adjuvant (after surgery) chemotherapy Clin ical Oncology, researchers announced that colorectal cancer patients that have a mutation in the KRAS gene do not respond to certain therapies, those that inhibit the epidermal growth factor receptor (EGFR)--namely Erb itu x (cetu ximab) and Vect ibix (panitu mu mab). 40 Following reco mmendations by ASCO, patients should now be tested for the KRAS gene mutation before being offered these EGFR-inhib iting drugs. In July 2009, the US Food and Drug Administration (FDA) updated the labels of two anti-EGFR monoclonal antibody drugs (panitumu mab (Vectib ix) and cetuximab (Erb itu x)) indicated for treatment of metastatic colorectal cancer to include info rmation about KRAS mutations.
